Journal Feed/Author

Halim Muhammad Sohail

🇴🇲 Smith-Kettlewell Eye Research Institute

ORCID OpenAlex2 articles in GJC

2 articles in GJC

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Beykin Gala, Stell Laurel, Halim Muhammad Sohail, Nuñez Mariana, Popova Lilia, Nguyen Bac T et al.

Am J OphthalmolAug 202211 citationsRandomized Controlled Trial

Full abstract PubMed

Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.

Beykin Gala, Stell Laurel, Halim Muhammad Sohail, Nuñez Mariana, Popova Lilia, Nguyen Bac T et al.

Am J OphthalmolNov 202131 citationsRandomized Controlled Trial

This study found topical rhNGF eye drops for glaucoma were safe and well-tolerated. While no significant short-term neuroenhancement was detected, trends suggest further neuroprotection trials are warranted.

Full abstract PubMed

All 2 articles loaded

Global Search

Halim Muhammad Sohail

Corrigendum to Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes. Am J Ophthalmol 2022;234:223-234.

Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.